Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 125,075
  • Shares Outstanding, K 15,518
  • Annual Sales, $ 0 K
  • Annual Income, $ -428 K
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade BCT.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.93
  • Most Recent Earnings -0.32 on N/A
  • Next Earnings Date 07/05/22
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.01 +9.56%
on 06/22/22
8.52 -9.86%
on 06/15/22
+0.36 (+4.92%)
since 06/06/22
3-Month
5.32 +44.36%
on 05/12/22
15.05 -48.97%
on 04/08/22
-5.80 (-43.03%)
since 04/06/22
52-Week
5.32 +44.36%
on 05/12/22
15.75 -51.24%
on 12/01/21
+1.70 (+28.43%)
since 07/06/21

Most Recent Stories

More News
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy

Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
Stocks in play: BriaCell Therapeutics Corp

Announced a research collaboration agreement with Harvard Medical School in support of a project led ...

BCT.TO : 7.68 (-4.71%)
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment

PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication....

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
Creatv Bio’s LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of metastatic breast cancer (mBC)...

BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell”...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
Stocks in play: BriaCell Therapeutics Corp.

Announced that the U.S. Food and Drug Administration has granted Fast Track status to BriaCell’s lead ...

BCT.TO : 7.68 (-4.71%)
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022

Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.Bria-OTS™ will...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial

Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™...

BCTXW : 2.90 (-3.33%)
BCTX : 5.95 (-4.19%)
BCT.TO : 7.68 (-4.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 8.45
2nd Resistance Point 8.27
1st Resistance Point 7.98
Last Price 7.68
1st Support Level 7.51
2nd Support Level 7.33
3rd Support Level 7.04

See More

52-Week High 15.75
Fibonacci 61.8% 11.77
Fibonacci 50% 10.53
Fibonacci 38.2% 9.30
Last Price 7.68
52-Week Low 5.32

See More

Business Summary

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar